Inhibition of the epigenetic modulator LSD1 in GDF1-positive HCC tumours strongly boosted the expression of CTAs, which might further sensitise HCC patients to immune-based therapies (Supplementary Fig. 8i). The gene discussed is KDM1A; the disease is hepatocellular carcinoma.